Diagnosing non‐acute heart failure (HF) remains challenging, notably in the early stages of the syndrome. The diagnostic value of mid‐regional pro‐atrial natriuretic peptide (MR‐proANP) has been proven in acute onset… Click to show full abstract
Diagnosing non‐acute heart failure (HF) remains challenging, notably in the early stages of the syndrome. The diagnostic value of mid‐regional pro‐atrial natriuretic peptide (MR‐proANP) has been proven in acute onset HF, but its role in early non‐acute HF is unknown. We aimed to determine the diagnostic value of MR‐proANP in suspected non‐acute HF.
               
Click one of the above tabs to view related content.